GlycoMimetics Stock Price, News & Analysis (NASDAQ:GLYC)

$16.51 0.50 (3.12 %)
(As of 12/17/2017 12:40 PM ET)
Previous Close$16.51
Today's Range$15.50 - $16.95
52-Week Range$3.82 - $18.25
Volume1.85 million shs
Average Volume807,517 shs
Market Capitalization$566.92 million
P/E RatioN/A
Dividend YieldN/A
Beta3.21

About GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GLYC
CUSIPN/A
Phone+1-240-2431201

Debt

Debt-to-Equity RatioN/A
Current Ratio17.44%
Quick Ratio17.44%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales28,347.67
Cash FlowN/A
Price / CashN/A
Book Value$1.53 per share
Price / Book10.79

Profitability

Trailing EPS($1.24)
Net Income$-31,800,000.00
Net MarginsN/A
Return on Equity-44.45%
Return on Assets-40.83%

Miscellaneous

Employees42
Outstanding Shares34,340,000

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. View GlycoMimetics' Earnings History.

Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?

6 brokerages have issued twelve-month target prices for GlycoMimetics' shares. Their predictions range from $12.00 to $32.00. On average, they expect GlycoMimetics' stock price to reach $21.60 in the next twelve months. View Analyst Ratings for GlycoMimetics.

What are Wall Street analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:

  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (11/13/2017)
  • 2. Cowen Inc analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)

Who are some of GlycoMimetics' key competitors?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board (Age 74)
  • Rachel K. King, President, Chief Executive Officer, Co-Founder, Director (Age 57)
  • John Magnani Ph.D., Co-Founder, Senior Vice President, Chief Scientific Officer, Director (Age 64)
  • Brian Hahn, Chief Financial Officer (Age 42)
  • Helen M. Thackray M.D., , Senior Vice President - Clinical Development, Chief Medical Officer (Age 47)
  • Patricia S. Andrews, Director
  • Mark Alan Goldberg M.D., Independent Director (Age 62)
  • Daniel M. Junius, Independent Director (Age 64)
  • Scott Koenig M.D., Ph.D., Independent Director (Age 64)
  • Timothy R. Pearson, Independent Director (Age 49)

Who owns GlycoMimetics stock?

GlycoMimetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (1.42%), EAM Investors LLC (1.13%), Alyeska Investment Group L.P. (1.05%), Columbus Circle Investors (0.62%), Citadel Advisors LLC (0.18%) and TD Asset Management Inc. (0.08%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.

Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?

GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC and TD Asset Management Inc.. View Insider Buying and Selling for GlycoMimetics.

Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?

GlycoMimetics' stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Citadel Advisors LLC, EAM Investors LLC, Fox Run Management L.L.C., Alyeska Investment Group L.P. and Dynamic Technology Lab Private Ltd. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.

How do I buy GlycoMimetics stock?

Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GlycoMimetics stock can currently be purchased for approximately $16.51.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $566.92 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-31,800,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. GlycoMimetics employs 42 workers across the globe.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 Medical Center Dr, ROCKVILLE, MD 20850-3343, United States. The biotechnology company can be reached via phone at +1-240-2431201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (GLYC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlycoMimetics (NASDAQ:GLYC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.60$18.20$14.75$12.50
Price Target Upside: 31.15% upside73.17% upside26.94% upside13.12% upside

GlycoMimetics (NASDAQ:GLYC) Consensus Price Target History

Price Target History for GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ:GLYC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017Stifel NicolausReiterated RatingBuy$23.00MediumView Rating Details
12/12/2017SunTrust BanksBoost Price TargetBuy$32.00HighView Rating Details
12/6/2017CowenReiterated RatingBuyLowView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$16.00N/AView Rating Details
10/23/2017Roth CapitalInitiated CoverageBuy$25.00N/AView Rating Details
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00HighView Rating Details
(Data available from 12/17/2015 forward)

Earnings

GlycoMimetics (NASDAQ:GLYC) Earnings History and Estimates Chart

Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ GLYC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.28)($0.24)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.37)($0.30)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.34)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.35)($0.36)$4.50 millionViewN/AView Earnings Details
11/4/2016Q216($0.44)($0.34)$0.02 millionViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.38)$2.10 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.40)$0.51$20.04 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014Q2 2014$0.24$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

GlycoMimetics (NASDAQ:GLYC) Earnings Estimates

2017 EPS Consensus Estimate: ($1.32)
2018 EPS Consensus Estimate: ($0.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.38)($0.37)($0.38)
Q2 20172($0.40)($0.30)($0.35)
Q3 20172($0.43)($0.25)($0.34)
Q4 20172($0.26)($0.25)($0.26)
Q1 20182($0.27)($0.25)($0.26)
Q2 20182($0.29)($0.27)($0.28)
Q3 20182($0.33)($0.30)($0.32)
Q4 20182($0.31)$1.16$0.43
(Data provided by Zacks Investment Research)

Dividends

Dividend History for GlycoMimetics (NASDAQ:GLYC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GlycoMimetics (NASDAQ GLYC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 86.81%
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ GLYC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Helen M ThackraySVPSell2,000$15.01$30,020.00View SEC Filing  
9/18/2017Helen M ThackraySVPSell2,000$13.00$26,000.00View SEC Filing  
5/25/2017Helen M ThackraySVPSell2,000$15.57$31,140.00View SEC Filing  
5/19/2017Helen M ThackraySVPSell2,000$12.14$24,280.00View SEC Filing  
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlycoMimetics (NASDAQ GLYC) News Headlines

Source:
DateHeadline
GlycoMimetics Added To NASDAQ Biotechnology Index - Business Wire (press release)GlycoMimetics Added To NASDAQ Biotechnology Index - Business Wire (press release)
www.businesswire.com - December 17 at 9:59 AM
Here's Why GlycoMimetics Could Become a Takeover TargetHere's Why GlycoMimetics Could Become a Takeover Target
finance.yahoo.com - December 17 at 9:59 AM
GlycoMimetics Added To NASDAQ Biotechnology IndexGlycoMimetics Added To NASDAQ Biotechnology Index
finance.yahoo.com - December 15 at 10:28 AM
GlycoMimetics Sees Unusually Large Options Volume (GLYC)GlycoMimetics Sees Unusually Large Options Volume (GLYC)
www.americanbankingnews.com - December 15 at 3:38 AM
Analysts Offer Predictions for GlycoMimetics, Inc.s FY2020 Earnings (GLYC)Analysts Offer Predictions for GlycoMimetics, Inc.'s FY2020 Earnings (GLYC)
www.americanbankingnews.com - December 14 at 9:46 PM
Equities Analysts Offer Predictions for GlycoMimetics, Inc.s FY2019 Earnings (GLYC)Equities Analysts Offer Predictions for GlycoMimetics, Inc.'s FY2019 Earnings (GLYC)
www.americanbankingnews.com - December 14 at 8:54 PM
GlycoMimetics (GLYC) "Buy" Rating Reiterated at Stifel NicolausGlycoMimetics' (GLYC) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - December 14 at 5:40 PM
Company News For Dec 13, 2017Company News For Dec 13, 2017
finance.yahoo.com - December 13 at 10:21 AM
Insider Selling: GlycoMimetics, Inc. (GLYC) SVP Sells 2,000 Shares of StockInsider Selling: GlycoMimetics, Inc. (GLYC) SVP Sells 2,000 Shares of Stock
www.americanbankingnews.com - December 12 at 6:30 PM
Here's Why GlycoMimetics Is Soaring 24.3% Higher TodayHere's Why GlycoMimetics Is Soaring 24.3% Higher Today
finance.yahoo.com - December 12 at 5:14 PM
GlycoMimetics Inc. (GLYC) Has Jumped To A New High On Study ResultsGlycoMimetics Inc. (GLYC) Has Jumped To A New High On Study Results
www.nasdaq.com - December 12 at 10:28 AM
GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271
finance.yahoo.com - December 12 at 10:28 AM
UPDATE: GlycoMimetics shares soar 30% after positive trial of leukemia treatmentUPDATE: GlycoMimetics shares soar 30% after positive trial of leukemia treatment
finance.yahoo.com - December 12 at 10:28 AM
GlycoMimetics (GLYC) Price Target Increased to $32.00 by Analysts at SunTrust BanksGlycoMimetics (GLYC) Price Target Increased to $32.00 by Analysts at SunTrust Banks
www.americanbankingnews.com - December 12 at 9:28 AM
GlycoMimetics (GLYC) Upgraded to "Hold" by BidaskClubGlycoMimetics (GLYC) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - December 10 at 3:46 PM
GlycoMimetics, Inc. (GLYC) Given Average Recommendation of "Buy" by AnalystsGlycoMimetics, Inc. (GLYC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 8 at 9:36 PM
GlycoMimetics (GLYC) Earns Buy Rating from CowenGlycoMimetics (GLYC) Earns Buy Rating from Cowen
www.americanbankingnews.com - December 7 at 3:38 PM
ASH: CBIO Awaiting Next Catalyst, BLUE In The Pink, STML Keeps GrowingASH: CBIO Awaiting Next Catalyst, BLUE In The Pink, STML Keeps Growing
www.rttnews.com - December 2 at 9:18 AM
What Is GlycoMimetics Inc’s (GLYC) Share Price Doing?What Is GlycoMimetics Inc’s (GLYC) Share Price Doing?
finance.yahoo.com - November 27 at 5:40 PM
Selectin Inhibition Justifies GlycoMimetics InvestmentSelectin Inhibition Justifies GlycoMimetics Investment
seekingalpha.com - November 16 at 2:46 PM
GlycoMimetics, Inc. (GLYC) Stock Rating Upgraded by Zacks Investment ResearchGlycoMimetics, Inc. (GLYC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:46 PM
GlycoMimetics, Inc. (GLYC) Receives Consensus Rating of "Buy" from AnalystsGlycoMimetics, Inc. (GLYC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 13 at 9:34 PM
SunTrust Banks Comments on GlycoMimetics, Inc.s Q1 2018 Earnings (GLYC)SunTrust Banks Comments on GlycoMimetics, Inc.'s Q1 2018 Earnings (GLYC)
www.americanbankingnews.com - November 13 at 6:00 AM
Jefferies Group Comments on GlycoMimetics, Inc.s FY2017 Earnings (GLYC)Jefferies Group Comments on GlycoMimetics, Inc.'s FY2017 Earnings (GLYC)
www.americanbankingnews.com - November 13 at 3:36 AM
Analyzing GlycoMimetics (GLYC) and Its PeersAnalyzing GlycoMimetics (GLYC) and Its Peers
www.americanbankingnews.com - November 12 at 11:54 PM
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences - Business Wire (press release)GlycoMimetics to Present at Upcoming Healthcare Investor Conferences - Business Wire (press release)
www.businesswire.com - November 11 at 6:59 AM
GlycoMimetics, Inc. (GLYC) to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group ForecastsGlycoMimetics, Inc. (GLYC) to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 10:50 AM
GlycoMimetics, Inc. (GLYC) Posts Quarterly  Earnings Results, Beats Expectations By $0.04 EPSGlycoMimetics, Inc. (GLYC) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - November 9 at 6:33 PM
GlycoMimetics Reports Program Updates and Third Quarter 2017 Results - Business Wire (press release)GlycoMimetics Reports Program Updates and Third Quarter 2017 Results - Business Wire (press release)
www.businesswire.com - November 9 at 6:09 AM
Edited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 6:09 AM
GlycoMimetics, Inc. to Host Earnings CallGlycoMimetics, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 8:05 AM
GlycoMimetics Reports Program Updates and Third Quarter 2017 ResultsGlycoMimetics Reports Program Updates and Third Quarter 2017 Results
finance.yahoo.com - November 8 at 8:05 AM
Why Earnings Season Could Be Great for GlycoMimetics (GLYC) - NasdaqWhy Earnings Season Could Be Great for GlycoMimetics (GLYC) - Nasdaq
www.nasdaq.com - November 2 at 8:53 PM
Why Earnings Season Could Be Great for GlycoMimetics (GLYC)Why Earnings Season Could Be Great for GlycoMimetics (GLYC)
finance.yahoo.com - November 2 at 8:53 PM
GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH MeetingGlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting
finance.yahoo.com - November 1 at 8:43 PM
GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - November 1 at 8:43 PM
GlycoMimetics, Inc. (GLYC) Rating Reiterated by Jefferies Group LLCGlycoMimetics, Inc. (GLYC) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 26 at 2:44 PM
GlycoMimetics, Inc. (GLYC) Coverage Initiated by Analysts at Roth CapitalGlycoMimetics, Inc. (GLYC) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - October 23 at 10:40 PM
GlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by AnalystsGlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 19 at 8:46 PM
GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : October 17, 2017GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : October 17, 2017
finance.yahoo.com - October 17 at 7:49 PM
GlycoMimetics, Inc. (GLYC) Lowered to Hold at Zacks Investment ResearchGlycoMimetics, Inc. (GLYC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM
GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017
finance.yahoo.com - October 16 at 3:48 PM
Head-To-Head Contrast: GlycoMimetics (GLYC) versus Its CompetitorsHead-To-Head Contrast: GlycoMimetics (GLYC) versus Its Competitors
www.americanbankingnews.com - October 16 at 2:10 AM
GlycoMimetics, Inc. (GLYC) Upgraded at Zacks Investment ResearchGlycoMimetics, Inc. (GLYC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 6 at 11:14 PM
GlycoMimetics, Inc. (GLYC) Receives "Buy" Rating from SunTrust Banks, Inc.GlycoMimetics, Inc. (GLYC) Receives "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - October 4 at 9:14 PM
BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mlnBRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln
www.reuters.com - September 28 at 8:29 PM
GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% HigherGlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher
finance.yahoo.com - September 26 at 11:40 AM
GlycoMimetics Inc (GLYC) Receives Consensus Rating of "Hold" from BrokeragesGlycoMimetics Inc (GLYC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 24 at 8:34 PM
GlycoMimetics, Inc. (GLYC) SVP Sells $26,000.00 in StockGlycoMimetics, Inc. (GLYC) SVP Sells $26,000.00 in Stock
www.americanbankingnews.com - September 18 at 8:10 PM
GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017
finance.yahoo.com - September 11 at 7:37 PM

SEC Filings

GlycoMimetics (NASDAQ:GLYC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlycoMimetics (NASDAQ:GLYC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlycoMimetics (NASDAQ GLYC) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.